☆ 4.7 Review

An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer-A Systematic Review of Randomized Phase II and III Clinical Trials

BIOMOLECULES (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Stephen R. D. Johnston et al.

Summary: In patients with high-risk hormone receptor-positive, HER2-negative early breast cancer, adjuvant abemaciclib plus endocrine therapy improves invasive disease-free survival and distant relapse-free survival. The benefit of abemaciclib extends beyond the completion of treatment, supporting its use in this patient population.

LANCET ONCOLOGY (2023)

Add to Collection

Review Oncology

The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis

Fausto Petrelli et al.

Summary: This pooled analysis demonstrates that adding CDK4/6 inhibitors to standard endocrine therapy significantly reduces mortality risk and improves overall survival and progression-free survival in elderly patients with advanced ER+ breast cancer.

BREAST (2023)

Add to Collection

Article Oncology

Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).

Gabe S. Sonke et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Economics

Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2-Metastatic Breast Cancer in Postmenopausal Women in the USA

Prajakta P. Masurkar et al.

Summary: This study evaluated the cost effectiveness of using CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) with letrozole in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. The study found that compared to letrozole alone, the cost effectiveness ratio of combining abemaciclib and letrozole was $457,538 per QALY gained.

PHARMACOECONOMICS (2023)

Add to Collection

Review Medicine, General & Internal

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer-A Review of the Literature

Ioana-Miruna Stanciu et al.

Summary: The combination therapy of CDK4/6 inhibitors and endocrine therapy represents a breakthrough treatment for advanced HR+ and HER2- breast cancer. However, drug resistance remains a challenge. Personalized treatment and strategies to overcome resistance are the future direction of research in this field.

DIAGNOSTICS (2023)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

Gabriel N. Hortobagyi et al.

Summary: First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced breast cancer. Median overall survival was more than 12 months longer with ribociclib than with placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Breast Cancer Statistics, 2022

Angela N. Giaquinto et al.

Summary: This article provides an update on female breast cancer statistics in the United States, including data on incidence, mortality, survival, and mammography screening. It shows that breast cancer incidence rates have increased over the past few decades, driven by localized-stage and hormone receptor-positive disease. However, breast cancer mortality rates have been steadily declining since 1989, although at a slower pace in recent years. Despite lower incidence rates, there remains a racial disparity in breast cancer mortality, with higher rates among Black women compared to White women.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Oncology

Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4

Binghe Xu et al.

Summary: The PALOMA-4 study demonstrates the efficacy and safety of first-line palbociclib plus letrozole in postmenopausal Asian women with ER+/HER2- ABC. No new safety concerns were identified for the combination therapy.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Efficacy of cyclin-dependent kinase 4/6 inhibitors in patients with metastatic hormone positive breast cancer: a single institutional study from India

Sandip Ganguly et al.

Summary: This study reported the experience of using CDK4/6 inhibitors in patients with hormone positive metastatic breast cancer. The analysis of baseline characteristics, treatment details, and toxicity showed that CDK4/6 inhibitors have shown good efficacy in terms of PFS and OS, and are well tolerated. Liver metastases, low progesterone receptor positivity, and prior treatment are poor prognostic factors for patient outcomes.

ECANCERMEDICALSCIENCE (2022)

Add to Collection

Article Oncology

nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer

Erika Hamilton et al.

Summary: Abemaciclib showed single-agent activity in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. Adding tamoxifen did not significantly improve progression-free survival or objective response rate compared to abemaciclib monotherapy.

CLINICAL BREAST CANCER (2021)

Add to Collection

Article Oncology

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Erica L. Mayer et al.

Summary: The PALLAS trial investigated whether adding 2 years of palbociclib to adjuvant endocrine therapy could improve invasive disease-free survival in early-stage hormone-receptor-positive, HER2-negative breast cancer patients, but the results showed no significant benefit. The trial was then discontinued based on the lack of efficacy observed during the planned second interim analysis.

LANCET ONCOLOGY (2021)

Add to Collection

Review Oncology

Efficacy and Safety of CDK4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER-2-ABC Patients: A Systematic Review and Meta-Analysis

Yongyan Li et al.

Summary: The combination of CDK4/6 inhibitors and ET shows significantly improved clinical outcomes for patients with HR+/HER-2- ABC, including prolonged PFS, increased ORR, and higher CBR. Additionally, the safety profile of this combination therapy is acceptable.

CANCER INVESTIGATION (2021)

Add to Collection

Review Oncology

Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2-Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies

Abeer J. Al-Qasem et al.

Summary: Advanced stage breast cancer is incurable, and the combination of CDK4/6 inhibitors and endocrine therapy has become the standard treatment. However, resistance to this combined therapy is a major clinical challenge, and ongoing research is focused on identifying predictive biomarkers and developing novel treatment strategies. Due to the heterogeneity of resistance mechanisms, finding a universal predictive biomarker is unlikely, leading to exploration of new approaches such as liquid biopsy for identifying resistance mechanisms and potential biomarkers.

CANCERS (2021)

Add to Collection

Meeting Abstract Oncology

Efficacy of CDK4/6i in the visceral crisis setting: Result from a real-world database.

Shaheenah S. Dawood et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Aleix Prat et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Stephen R. D. Johnston et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts

Christoph Thomssen et al.

BREAST CARE (2020)

Add to Collection

Article Oncology

MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2-advanced breast cancer: the multinational randomized phase III study

Qing Yuan Zhang et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

S. -A. Im et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Oncology

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

Amelia McCartney et al.

FRONTIERS IN ONCOLOGY (2019)

Add to Collection

Article Oncology

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial

Stephen Johnston et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

Mary E. Klein et al.

CANCER CELL (2018)

Add to Collection

Article Oncology

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3

Dennis J. Slamon et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

N. C. Turner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

George W. Sledge et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Matthew P. Goetz et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Review Medicine, General & Internal

Breast cancer

Nadia Harbeck et al.

LANCET (2017)

Add to Collection

Article Oncology

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

Laura M. Spring et al.

ONCOLOGIST (2017)

Add to Collection

Article Oncology

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Raquel Torres-Guzman et al.

ONCOTARGET (2017)

Add to Collection

Article Medicine, General & Internal

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

G. N. Hortobagyi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Oncology

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial

Sarat Chandarlapaty et al.

JAMA ONCOLOGY (2016)

Add to Collection

Article Oncology

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn et al.

LANCET ONCOLOGY (2015)

Add to Collection

Review Biotechnology & Applied Microbiology

The history and future of targeting cyclin-dependent kinases in cancer therapy

Uzma Asghar et al.

NATURE REVIEWS DRUG DISCOVERY (2015)

Add to Collection

Article Oncology

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert et al.

INVESTIGATIONAL NEW DRUGS (2014)

Add to Collection

Article Public, Environmental & Occupational Health

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Alessandro Liberati et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)

Add to Collection

Article Oncology

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Richard S. Finn et al.

BREAST CANCER RESEARCH (2009)

Add to Collection

Article Oncology

Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database

WF Anderson et al.

BREAST CANCER RESEARCH AND TREATMENT (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.